Novartis To Build Radiopharmaceutical Mfg FacilityBy
Advanced Accelerator Applications (AAA), a Novartis company, has executed a sales and purchase agreement for a 50,000-square-foot piece of land in Indianapolis, Indiana to build a radioligand therapy manufacturing plant.
The facility will expand AAA’s manufacturing capacity in the US and is intended to support near- and long-term manufacturing capacity planning for AAA’s marketed products and for clinical supply. Initially, several production lines will be installed with plans to further expand capacity. Completion of the plant and initial operations are scheduled for 2023. The plant will be AAA’s second manufacturing facility in the US.
Novartis acquired AAA, a Saint-Genis-Pouilly, France-headquartered radiopharmaceutical company, for $3.9-billion in January 2018. Its key commercial product is Lutathera (lutetium Lu 177 dotatate), a radiopharmaceutical for treating gastroenteropancreatic neuroendocrine tumors. The drug had 2019 global sales of $441 million.